<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269046</url>
  </required_header>
  <id_info>
    <org_study_id>LML</org_study_id>
    <nct_id>NCT02269046</nct_id>
  </id_info>
  <brief_title>Acupuncture and Moxibustion for Hyperlipemia</brief_title>
  <acronym>AMH-RCT</acronym>
  <official_title>A Multi-center, Randomized, Stratified, Active-controlled Trial to Evaluate the Effects of Acupuncture and Moxibustion for Hyperlipidemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State Administration of Traditional Chinese Medicine of the People's Republic of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of 12 weeks of acupuncture and
      moxibustion compared with active control, on absolute and percent change from baseline in
      low-density lipoprotein cholesterol (LDL-C) among those with hyperlipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the effect of 12 weeks of acupuncture compared with active control, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) among those with hyperlipidemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>high-density lipoprotein cholesterol (HDL-C)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total cholesterol (TC)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglyceride(TG)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of subjects achieving LDL-C goal</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety summaries will include the subject incidence of adverse events, summaries of laboratory parameters (including shift tables), vital signs, and ECGs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adherence of acupuncture</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adherence to the treatment (adherence rate)will be calculated using formula:
Adherence Rate = Number of Treatment Conducted/ Number of Treatment Planned</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Acupuncture and moxibustion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>therapeutic lifestyle change
Group I:Juque (RN14), Tianshu (ST25, bilateral), Fenglong (ST40, bilateral), Zusanli (ST 36, bilateral), Sanyinjiao (SP6, bilateral)
Group II: Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
Group I and II will change alternatively every other week .
Once per day five days per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>therapeutic lifestyle change
simvastatin
oral administration with 10mg per day
seven days per week for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>waiting list</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>- therapeutic lifestyle change</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>acupuncture and moxibustion</intervention_name>
    <description>Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)</description>
    <arm_group_label>Acupuncture and moxibustion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>10mg/d,p.o,12 weeks.</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapeutic Lifestyle Change</intervention_name>
    <description>Reduced intakes of saturated fats (&lt;7% of total calories) and cholesterol (&lt;200 mg per day)
Therapeutic options for enhancing LDL lowering
Weight reduction
Increased physical activity</description>
    <arm_group_label>Acupuncture and moxibustion</arm_group_label>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_label>waiting list</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject signed the informed consent

          -  Male or female ≥18 to ≤75 years of age

          -  Fasting TG ≤400 mg/dL

          -  Fasting LDL-C as determined by central laboratory on admission and meeting the
             following LDL-C values based on risk factor status:

               -  0-1 Risk Factor Group: LDL-C ≥160 mg/dL

               -  2+ Risk Factor Group: LDL-C ≥130 mg/dL

               -  CHD or CHD risk equivalents: LDL-C ≥100 mg/dL

               -  Major Risk factors: （1）Cigarette smoking;（2）Hypertension (BP ≥140/90 mmHg or on
                  anti-hypertensive medication);（3）Low HDL cholesterol (HDL-C &lt;40 mg/dL);（4）Family
                  history of premature CHD (CHD in male first degree relative &lt;55 years; CHD in
                  female first degree relative &lt;65 years);（5）Age (men ≥45 years; women ≥55 years)

               -  CHD and CHD equivalents:（1）Other clinical forms of atherosclerotic disease
                  (peripheral arterial disease, abdominal aortic aneurysm, and symptomatic carotid
                  artery disease);（2）Diabetes;（3）Multiple risk factors that confer a 10-year risk
                  for CHD &gt;20%

        Exclusion Criteria:

          -  CHD or CHD risk equivalent and not receiving statin therapy, with LDL-C at screening
             ≤99 mg/dL

          -  NYHA II, III or IV heart failure, or last known left ventricular ejection fraction
             &lt;30%

          -  Uncontrolled cardiac arrhythmia, atrial fibrillation with rapid ventricular response,
             or not controlled supraventricular tachycardia in the past 3 months prior to
             randomization

          -  Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI),
             coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization

          -  Planned cardiac surgery or revascularization

          -  Type 1 diabetes or newly diagnosed type 2 diabetes or poorly controlled type 2
             diabetes

          -  Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) &gt;160 mmHg
             or diastolic BP (DBP) &gt;100 mmHg

          -  Subjects taken red yeast rice, niacin &gt;200 mg/d, or omega-3 fatty acids &gt;1000 mg/d or
             prescription lipid-regulating drugs other than statins or ezetimibe, such as fibrates
             and derivatives, or bile-acid sequestering resins in the last 6 weeks prior to LDL-C
             screening

          -  Subjects taken systemic cyclosporine, systemic steroids, vitamin A derivatives and
             retinol derivatives for the treatment of dermatologic conditions in the last 3 months
             prior to LDL-C screening

          -  Hyperthyroidism or hypothyroidism

          -  Moderate to severe renal dysfunction

          -  Active liver disease or hepatic dysfunction

          -  CK &gt;3 times the ULN at screening or at end of lipid stabilization period, confirmed by
             a repeat measurement at least 1 week apart

          -  Known active infection or major hematologic, renal, metabolic, gastrointestinal or
             endocrine dysfunction in the judgment of the investigator

          -  Deep vein thrombosis or pulmonary embolism within 3 months prior to randomization

          -  Current therapeutic anticoagulation with vitamin K antagonist, heparin, low-molecular
             weight heparin, direct thrombin inhibitor

          -  Currently enrolled in another investigational device or drug study

          -  Female subject during pregnant or breast feeding period

          -  History of malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma,
             breast ductal carcinoma in situ, or stage 1 prostate carcinoma)

          -  Known sensitivity to any of the products to be administered during dosing

          -  Subjects couldn't provide the written informed consent and/or comply with all required
             study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaorong Chang, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Hunan University of Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mailan Liu, Dr.</last_name>
    <phone>86-18229792024</phone>
    <email>445007305@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changsha Hospital of Chinese Medicine</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiong, Dr.</last_name>
      <email>973920892@qq.com</email>
    </contact>
    <investigator>
      <last_name>Xiong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Hospital of Hunan University of Chinese Medicine</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liu</last_name>
      <email>55999630@qq.com</email>
    </contact>
    <investigator>
      <last_name>Weiai Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Hospital of Hunan University of Chinese Medicine</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410007</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wang</last_name>
      <email>1835591292@qq.com</email>
    </contact>
    <investigator>
      <last_name>Feng Zhong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Yue ZH, He XQ, Chang XR, Yuan JL, Yu BS, Liu M, Fu L, Zhang L, Shang LC. The effect of herb-partition moxibustion on Toll-like receptor 4 in rabbit aorta during atherosclerosis. J Acupunct Meridian Stud. 2012 Apr;5(2):72-9. doi: 10.1016/j.jams.2012.01.005. Epub 2012 Feb 10.</citation>
    <PMID>22483185</PMID>
  </reference>
  <reference>
    <citation>Yue ZH, Yan J, Chang XR, Lin YP, Yi SX, Cao XP, Shen J. [Effects of cake-separated moxibustion on ultrastructures of endothelial cells of aorta in the rabbit of hyperlipemia]. Zhongguo Zhen Jiu. 2005 Jan;25(1):64-7. Chinese.</citation>
    <PMID>16309161</PMID>
  </reference>
  <reference>
    <citation>Xiaorong C, Jie Y, Zenghui Y, Jing S, Yaping L, Shouxiang Y, Xiangping C. Effects of medicinal cake-separated moxibustion on plasma 6-keto-PGF1alpha and TXB2 contents in the rabbit of hyperlipemia. J Tradit Chin Med. 2005 Jun;25(2):145-7.</citation>
    <PMID>16136949</PMID>
  </reference>
  <reference>
    <citation>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97.</citation>
    <PMID>11368702</PMID>
  </reference>
  <reference>
    <citation>Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12. Erratum in: Circulation. 2015 Dec 22;132(25):e396. Circulation. 2014 Jun 24;129(25 Suppl 2):S46-8.</citation>
    <PMID>24222016</PMID>
  </reference>
  <reference>
    <citation>Yan X, Chen H, Gao W, Li J, Yang X, Ye P, Zhang S, Zhao D, Zhu J, Huo Y. [Consensus standpoints from expert panel of Chinese Society of Cardiology on AHA/ACC 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults]. Zhonghua Xin Xue Guan Bing Za Zhi. 2014 Apr;42(4):275-6. Chinese.</citation>
    <PMID>24924450</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>October 16, 2014</last_update_submitted>
  <last_update_submitted_qc>October 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acupuncture</keyword>
  <keyword>moxibustion</keyword>
  <keyword>hyperlipidemias</keyword>
  <keyword>effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

